163 related articles for article (PubMed ID: 21199461)
1. Subcutaneous methotrexate is well tolerated and superior to oral methotrexate in the treatment of rheumatoid arthritis.
Hameed B; Jones H
Int J Rheum Dis; 2010 Oct; 13(4):e83-4. PubMed ID: 21199461
[No Abstract] [Full Text] [Related]
2. Subtherapeutic dosing of methotrexate in rheumatoid arthritis trials.
Parker CT; Mewshaw E; Dennis GJ
J Am Osteopath Assoc; 2004 Jan; 104(1):7-8. PubMed ID: 14992316
[No Abstract] [Full Text] [Related]
3. Limitations of the study of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: comment on the article by Braun et al.
Raghu P; Grover PS; Kumar A
Arthritis Rheum; 2008 Jul; 58(7):2209; author reply 2209-10. PubMed ID: 18576338
[No Abstract] [Full Text] [Related]
4. Better efficacy of methotrexate given by intramuscular injection than orally in patients with rheumatoid arthritis.
Wegrzyn J; Adeleine P; Miossec P
Ann Rheum Dis; 2004 Oct; 63(10):1232-4. PubMed ID: 15361377
[TBL] [Abstract][Full Text] [Related]
5. Are switches from oral to subcutaneous methotrexate or addition of ciclosporin to methotrexate useful steps in a tight control treatment strategy for rheumatoid arthritis? A post hoc analysis of the CAMERA study.
Bakker MF; Jacobs JW; Welsing PM; van der Werf JH; Linn-Rasker SP; van der Veen MJ; Lafeber FP; Bijlsma JW;
Ann Rheum Dis; 2010 Oct; 69(10):1849-52. PubMed ID: 20511610
[TBL] [Abstract][Full Text] [Related]
6. Self-injection of gold and methotrexate.
Arthur V; Jubb R; Homer D
J Rheumatol; 2001 Jan; 28(1):212. PubMed ID: 11196528
[No Abstract] [Full Text] [Related]
7. Bioavailability of higher dose MTX comparing oral and subcutaneous administration in patients with RA.
Rau R
J Rheumatol; 2005 Jul; 32(7):1412; author reply 1412-3. PubMed ID: 15996092
[No Abstract] [Full Text] [Related]
8. Comment on: Use of parenteral methotrexate significantly reduces the need for biological therapy.
Thornton C; Ong V; Ward J; Kennedy N; Steuer A
Rheumatology (Oxford); 2008 Sep; 47(9):1438; author reply 1438. PubMed ID: 18617550
[No Abstract] [Full Text] [Related]
9. [Subcutaneous self-administration of methotrexate in rheumatoid arthritis].
Huisman AM; Schouten JP; van Paassen HC; Wouters JM; Jacobs JW
Ned Tijdschr Geneeskd; 1996 Jul; 140(30):1564-5. PubMed ID: 8765767
[No Abstract] [Full Text] [Related]
10. Lack of association between elevated mean red cell volume and haematological toxicity in patients receiving long-term methotrexate for rheumatoid arthritis.
White DH; Chapman PT; O'Donnell JL; James J; Frampton C; Stamp LK
Intern Med J; 2010 Aug; 40(8):561-5. PubMed ID: 19811562
[TBL] [Abstract][Full Text] [Related]
11. Combination drug therapy of seropositive rheumatoid arthritis.
McCarty DJ; Harman JG; Grassanovich JL; Qian C; Klein JP
J Rheumatol; 1995 Sep; 22(9):1636-45. PubMed ID: 8523336
[TBL] [Abstract][Full Text] [Related]
12. Changing patterns in the use of slow acting antirheumatic drugs for the treatment of rheumatoid arthritis.
Horsfall MW; Shaw JP; Highton J; Cranch PJ
N Z Med J; 1998 Jun; 111(1067):200-3. PubMed ID: 9673632
[TBL] [Abstract][Full Text] [Related]
13. Discontinuing treatment in patients with rheumatoid arthritis in sustained clinical remission: exploratory analyses from the BeSt study.
Klarenbeek NB; van der Kooij SM; Güler-Yüksel M; van Groenendael JH; Han KH; Kerstens PJ; Huizinga TW; Dijkmans BA; Allaart CF
Ann Rheum Dis; 2011 Feb; 70(2):315-9. PubMed ID: 21068104
[TBL] [Abstract][Full Text] [Related]
14. Comparison of two schedules for administering oral low-dose methotrexate (weekly versus every-other-week) in patients with rheumatoid arthritis in remission: a twenty-four week, single blind, randomized study.
Luis M; Pacheco-Tena C; Cazarín-Barrientos J; Lino-Pérez L; Goycochea MV; Vazquez-Mellado J; Burgos-Vargas R
Arthritis Rheum; 1999 Oct; 42(10):2160-5. PubMed ID: 10524688
[TBL] [Abstract][Full Text] [Related]
15. Can very high-dose anti-tumor necrosis factor blockade at onset of rheumatoid arthritis produce long-term remission?
Conaghan PG; Quinn MA; O'Connor P; Wakefield RJ; Karim Z; Emery P
Arthritis Rheum; 2002 Jul; 46(7):1971-2; author reply 1973. PubMed ID: 12124886
[No Abstract] [Full Text] [Related]
16. Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis.
Hoekstra M; Haagsma C; Neef C; Proost J; Knuif A; van de Laar M
J Rheumatol; 2004 Apr; 31(4):645-8. PubMed ID: 15088287
[TBL] [Abstract][Full Text] [Related]
17. Methotrexate polyglutamate concentrations are not associated with disease control in rheumatoid arthritis patients receiving long-term methotrexate therapy.
Stamp LK; O'Donnell JL; Chapman PT; Zhang M; James J; Frampton C; Barclay ML
Arthritis Rheum; 2010 Feb; 62(2):359-68. PubMed ID: 20112376
[TBL] [Abstract][Full Text] [Related]
18. [Comparison of efficacy and tolerability of triple combination therapy (methotrexate + sulfasalazine + hydroxychloroquine) with methotrexate monotherapy in patients with rheumatoid arthritis].
Gubar' EE; Bochkova AG; Bunchuk NV
Ter Arkh; 2008; 80(5):25-30. PubMed ID: 18590110
[TBL] [Abstract][Full Text] [Related]
19. Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial.
O'Dell JR; Leff R; Paulsen G; Haire C; Mallek J; Eckhoff PJ; Fernandez A; Blakely K; Wees S; Stoner J; Hadley S; Felt J; Palmer W; Waytz P; Churchill M; Klassen L; Moore G
Arthritis Rheum; 2002 May; 46(5):1164-70. PubMed ID: 12115219
[TBL] [Abstract][Full Text] [Related]
20. [The initial results of the Metex Study].
Braun J
Krankenpfl J; 2005; 43(7-10):246-7. PubMed ID: 16515316
[No Abstract] [Full Text] [Related]
[Next] [New Search]
